Detailed narrative
Strategic Repositioning to Immunology
Spero Therapeutics has strategically repositioned itself as an immunology-focused company following the FDA approval of Utebzi. This pivot is anchored by the in-licensing of SP001, a third-generation fully humanized Fc silent IgG1 monoclonal antibody targeting CD40 ligand. The company aims to address high unmet medical needs in immune-mediated diseases, leveraging its experienced team for clinical development and commercialization.
Utebzi FDA Approval and Commercialization
On June 17, 2026, the FDA approved Utebzi (tebipenem pivoxil) for complicated urinary tract infections, including pyelonephritis, caused by certain susceptible pathogens. This marks Utebzi as the first and only oral carbapenem antibiotic approved in the U.S. The approval was based on the PIVOT-PO Phase III study, which was stopped early for efficacy in May 2025.
GSK holds exclusive commercialization rights worldwide (excluding certain Asian territories), and expects Utebzi to be available to U.S. patients in the second half of 2026.
SP001 In-Licensing and Development Plan
Spero announced an exclusive license agreement with Innovent Biologics for SP001 (IBI355) on July 8, 2026, granting Spero worldwide rights excluding Greater China. SP001 has completed two Phase I studies in healthy volunteers and a Phase Ib study in primary Sjogren's disease.
The company intends to advance SP001 into a Phase II trial for immunoglobulin G4-related disease (IgG4-RD), with initiation expected in Q2 2027. The planned Phase II trial will be open-label, with 6 monthly dosing, enrolling up to 15 patients in each of two dosing arms.
Strategic Financing and Balance Sheet Strength
On July 8, 2026, Spero closed a $105 million nondilutive, nonrecourse royalty financing with affiliates of Healthcare Royalty, a KKR business. This financing involved a special purpose subsidiary issuing senior secured notes with a 10% annual interest rate and a 9-year maturity, payable from GSK's Utebzi milestone and royalty payments.
Spero retains 35% of additional GSK proceeds after note repayment. This transaction significantly strengthened the balance sheet, providing capital for the new immunology strategy and extending the cash runway into the second half of 2029.
Leadership Appointment
Dr. Debra Zack joined Spero as Chief Medical Officer on August 3, 2026. Dr. Zack is a Board-certified rheumatologist with a PhD in immunology and extensive drug development experience from companies like Amgen, Xencor, and Novartis. She will lead the clinical development strategy for SP001 and the broader immunology pipeline.
IgG4-RD Market Opportunity and SP001 Differentiation
IgG4-RD is a serious chronic fibroinflammatory disease affecting 20,000 to 40,000 diagnosed patients in the U.S., with diagnosis rates expected to increase due to a recently implemented disease-specific diagnostic code (October 2023). Current treatments are off-label steroids or B-cell depleters, which lead to cycles of remission and relapse.
SP001, by targeting CD40 ligand, aims to offer a differentiated approach by disrupting the pathologic interaction between T cells and B cells, potentially modulating multiple components of the disease process simultaneously and providing more durable long-term control.